<i>MYD88</i> L265P mutation and interleukin?10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a prospective study

Reliable biomarkers are needed to avoid diagnostic delay and its devastating effects in patients with primary central nervous system (CNS) lymphoma (PCNSL). We analysed the discriminating sensitivity specificity of myeloid differentiation response (88) (MYD88) L265P mutation (mut-MYD88) interleukin-10 (IL-10) cerebrospinal fluid (CSF) both newly diagnosed (n = 36) relapsed 27) PCNSL 162 controls (118 CNS disorders 44 extra-CNS lymphomas). The concordance MYD88 mutational status between tumour tissue CSF sample source ILs tissues were also investigated. Mut-MYD88 was assessed by TaqMan-based polymerase chain reaction. IL-6 IL-10 messenger RNA (mRNA) on biopsies using RNAscope technology. IL levels enzyme-linked immunosorbent assay. detected 15/17 (88%) biopsies, an 82% paired tissue-CSF samples. mRNA lymphomatous B cells most PCNSL; expression transcripts negligible. In samples, mut-MYD88 high detected, respectively, 72% 88% 1% controls; conversely, showed a low specificity. Combined analysis exhibits distinguish 94% 98% respectively. Similar figures recorded PCNSL. conclusion, detection rates reflect, synthesis this tissue. These exhibit very detecting at initial diagnosis relapse. Implications these findings lesions unsuitable for biopsy deserve be